Charles Schwab Investment Management Inc. Has $89.12 Million Position in Hologic, Inc. (NASDAQ:HOLX)

Charles Schwab Investment Management Inc. decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 2.0% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,442,704 shares of the medical equipment provider's stock after selling 29,145 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.64% of Hologic worth $89,116,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of HOLX. Federated Hermes Inc. grew its stake in Hologic by 35.8% in the 4th quarter. Federated Hermes Inc. now owns 7,720 shares of the medical equipment provider's stock worth $557,000 after acquiring an additional 2,036 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Hologic during the fourth quarter valued at $27,007,000. Sterling Capital Management LLC lifted its holdings in Hologic by 51.3% during the fourth quarter. Sterling Capital Management LLC now owns 14,099 shares of the medical equipment provider's stock valued at $1,016,000 after purchasing an additional 4,779 shares in the last quarter. Canada Post Corp Registered Pension Plan purchased a new position in shares of Hologic in the fourth quarter worth about $234,000. Finally, Aware Super Pty Ltd as trustee of Aware Super purchased a new position in shares of Hologic in the fourth quarter worth about $734,000. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Stock Down 0.4%

Shares of NASDAQ HOLX traded down $0.25 during trading hours on Friday, hitting $67.81. The stock had a trading volume of 4,294,477 shares, compared to its average volume of 1,738,030. The company has a market capitalization of $15.08 billion, a P/E ratio of 28.14, a P/E/G ratio of 2.46 and a beta of 0.49. The firm's 50-day moving average price is $65.60 and its two-hundred day moving average price is $62.57. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.39. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%. The company's quarterly revenue was up 1.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.06 earnings per share. Analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

HOLX has been the subject of a number of research reports. Morgan Stanley lifted their price objective on shares of Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a report on Thursday, July 31st. Wall Street Zen cut shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Evercore ISI increased their price objective on shares of Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Mizuho set a $75.00 price target on shares of Hologic in a research note on Thursday, July 31st. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Ten research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $77.83.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.